| abstract |
The present invention relates, in part, to agents that bind PD-L1 and the use of such agents as diagnostic and therapeutic agents. The present invention also relates to a pharmaceutical composition comprising a PD-L1 targeting moiety and the use of the pharmaceutical composition in the treatment of various diseases. In various aspects, the invention relates to binding agents having at least one targeting moiety that specifically binds to PD-1 or PD-L1. In various embodiments, these binding agents bind to PD-1 or PD-L1 and functionally modulate (eg, partially or fully neutralize) PD-1 or PD-L1. |